نتائج البحث - "Marta Castroviejo‐Bermejo"

المساهمون: Institut Català de la Salut, [Serra V] Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. CIBERONC, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Wang AT, Polanska UM] AstraZeneca Oncology R&D, Cambridge, United Kingdom. [Castroviejo-Bermejo M, Palafox M, Llop-Guevara A, Guzman M, Rodríguez O, Grueso J] Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Herencia-Ropero A] Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Arribas J] CIBERONC, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Growth Factors Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Cortés J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Saura C] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Breast Cancer and Melanoma Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Cruz C] Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. High Risk and Familial Cancer, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Balmaña J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. High Risk and Familial Cancer, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Cancer Research, Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], Antineoplastic Agents, Cell Cycle Proteins, Ataxia Telangiectasia Mutated Proteins, neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas [ENFERMEDADES], Carcinoma, Ovarian Epithelial, Poly(ADP-ribose) Polymerase Inhibitors, Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors [CHEMICALS AND DRUGS], Humans, Other subheadings::/therapeutic use [Other subheadings], Protein Kinase Inhibitors, Ovarian Neoplasms, neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas [COMPUESTOS QUÍMICOS Y DROGAS], Otros calificadores::/uso terapéutico [Otros calificadores], BRCA1 Protein, Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms [DISEASES], Nucleosides, Ovaris - Càncer - Tractament, Protein-Tyrosine Kinases, Oncology, Mama - Càncer - Tractament, Phthalazines, Female, Biomarkers, Proteïnes quinases - Inhibidors - Ús terapèutic

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9955a2728db6883e285333066588d50e
https://pubmed.ncbi.nlm.nih.gov/35921524

6

1O Detection of homologous recombination repair deficiency (HRD) in treatment-naive early triple-negative breast cancer (TNBC) by RAD51 foci and comparison with DNA-based tests

المصدر: Annals of Oncology. 32:S21-S22

مصطلحات موضوعية: Therapy naive, chemistry.chemical_compound, Oncology, chemistry, business.industry, RAD51, Cancer research, Medicine, Hematology, business, Homologous recombination, DNA, Triple-negative breast cancer

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::9283e94d2952b2f3c5c5137ea6e33020
https://doi.org/10.1016/j.annonc.2021.03.015

7

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

المساهمون: Bruna, Alejandra [0000-0003-1214-9665], Caldas, Carlos [0000-0003-3547-1489], Apollo - University of Cambridge Repository

المصدر: Annals of Oncology
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid

مصطلحات موضوعية: 0301 basic medicine, endocrine system diseases, RAD51, homologous recombination, Poly (ADP-Ribose) Polymerase Inhibitor, Mice, chemistry.chemical_compound, 0302 clinical medicine, Breast Tumors, Medicine, Breast, skin and connective tissue diseases, Exome sequencing, BRCA1 Protein, Hematology, 3. Good health, Treatment Outcome, Germline BRCA, Oncology, germline BRCA, 030220 oncology & carcinogenesis, PARP inhibitor, Biomarker (medicine), Female, TP53BP1, DNA damage, Mice, Nude, Breast Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, Olaparib, 03 medical and health sciences, Germline mutation, Biomarkers, Tumor, Animals, Humans, Homologous recombination, Germ-Line Mutation, Retrospective Studies, BRCA2 Protein, business.industry, Recombinational DNA Repair, Original Articles, Xenograft Model Antitumor Assays, 030104 developmental biology, chemistry, Drug Resistance, Neoplasm, ATM, PARP inhibitor resistance, Cancer research, Rad51 Recombinase, business

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cac37072c81f83232b13085f5ef04dc
https://doi.org/10.1093/annonc/mdy099

8

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

المساهمون: Jonkers, Jos [0000-0002-9264-9792], Balmaña, Judith [0000-0002-0762-6415], Serra, Violeta [0000-0001-6620-1065], Apollo - University of Cambridge Repository

المصدر: Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
EMBO Molecular Medicine
EMBO Molecular Medicine, Vol 10, Iss 12, Pp n/a-n/a (2018)

مصطلحات موضوعية: 0301 basic medicine, Medicine (General), RAD51, homologous recombination, QH426-470, Piperazines, chemistry.chemical_compound, Mice, 0302 clinical medicine, Medicine, PARP inhibitors, Research Articles, Cancer, education.field_of_study, 3. Good health, 030220 oncology & carcinogenesis, PARP inhibitor, Molecular Medicine, Biomarker (medicine), Heterografts, Female, Research Article, PALB2, Population, Antineoplastic Agents, Breast Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, Olaparib, 03 medical and health sciences, R5-920, Breast cancer, Genetics, Biomarkers, Tumor, Animals, Humans, Pharmacology & Drug Discovery, education, Biomarkers & Diagnostic Imaging, business.industry, Inhibitors, BRCA mutation, medicine.disease, BRCA1, 030104 developmental biology, chemistry, Drug Resistance, Neoplasm, Cancer research, Phthalazines, Rad51 Recombinase, business